文献速递腹部技术与安全PET

新型抗CEACAM6抗体偶联物用于胰腺导管腺癌放射免疫诊疗的评估

Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma.
PubMed 文献 · Eur Radiol · 2023-05-11

研究基于骆驼源重链单域抗体制备靶向CEACAM6的重组抗体NY004,并用诊疗核素标记,在胰腺导管腺癌模型中行microPET显像与生物分布及抗肿瘤评估。[89Zr]-NY004在PANC-1肿瘤中靶向摄取高、滞留时间长(注射后达6天),特异性和显像效率好;[177Lu]-NY004在肿瘤中摄取高且持久、非靶器官摄取相对低、抑瘤效果好。作者认为NY004是CEACAM6阳性肿瘤放射免疫诊疗的有前景的药物平台。

要点

  • [89Zr]-NY004在PANC-1肿瘤中靶向摄取高、滞留时间长,注射后达6天。
  • [177Lu]-NY004在肿瘤中摄取高且持久,非靶器官摄取相对低,抑瘤效果好。
  • NY004为骆驼源重链单域抗体,易于标记且靶向特异性好。

核心结论

  • CEACAM6特异性抗体NY004作为放射诊疗药物平台,满足易于标记、靶向特异性和在胰腺腺癌组织中有效持久的要求。

研究设计与样本

  • 基于骆驼源重链单域抗体制备靶向CEACAM6的重组抗体NY004,用诊疗核素标记后在胰腺导管腺癌肿瘤模型中行microPET显像、免疫组化和生物分布检测及抗肿瘤评估。

关键影像表现/征象

  • [89Zr]-NY004在包括胰腺导管腺癌在内的实体瘤中靶向摄取高、肿瘤滞留时间长(注射后达6天),特异性和显像效率好。
  • 所研究的肿瘤均为CEACAM6阳性恶性肿瘤。
  • [177Lu]-NY004在胰腺导管腺癌荷瘤模型中肿瘤摄取高且持久,非靶器官摄取相对低。

诊断标准与关键数值

  • 以CEACAM6表达阳性作为NY004靶向诊疗的肿瘤选择条件,所研究肿瘤均为CEACAM6阳性恶性肿瘤。
  • [89Zr]-NY004在PANC-1肿瘤中滞留时间达注射后6天。

临床应用与阅片要点

  • 作者认为NY004是CEACAM6阳性肿瘤(包括胰腺导管腺癌)放射免疫诊疗的有前景的药物平台。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant solid tumor that lacks early diagnostic methods. Recently, targeted immunotherapy and radiotherapy have been integrated with radionuclide-antibody conjugate drugs, which can be used for targeted diagnosis and dynamic imaging of tumors. CEACAM6 is overexpressed in pancreatic tumors and is a potential theranostic target for PDAC. We aimed to develop a novel targeted carrier for theranostics of PDAC and other solid tumors.

METHODS: Based on camelid heavy-chain-only antibodies, we developed a CEACAM6-targeting recombinant antibody NY004, and evaluated it as a novel antibody-carrier for imaging and therapy of cancer in tumor models. We labeled NY004 with theranostic nuclides and applied this self-developed antibody platform in diagnostic imaging and antitumor assessment in PDAC models.

RESULTS: Through microPET, IHC, and biodistribution assays, targeting and biodistribution of [89Zr]-NY004 in solid tumors including PDAC was examined, and the investigated tumors were all CEACAM6-positive malignancies. We found that NY004 was suitable for use as a drug carrier for radioimmunotheranostics. Our study showed that NY004 was characterized by high targeted uptake and a long retention time in PANC-1 tumors (up to 6 days post-injection), with good specificity and high imaging efficiency. Therapeutic evaluation of the radionuclide-labeled antibody drug [177Lu]-NY004 in PDAC tumor-bearing model revealed that NY004 had high and prolonged uptake in tumors, relatively low non-target organ uptake, and good anti-tumor efficacy.

CONCLUSION: As a drug platform for radiotheranostics, CEACAM6-specific antibody NY004 met the requirements of easy-labeling, targeting specificity, and effective persistence in pancreatic adenocarcinoma tissues.

KEY POINTS: • [89Zr]-NY004 has good specificity and high imaging efficiency, and is characterized by high tumor-targeting uptake and a long tumor retention time as a PET molecular imaging tracer. • Therapeutic radionuclide-conjugated antibody drug [177Lu]-NY004 has high uptake and prolonged uptake duration in tumors, low non-target organ uptake, and significant tumor-inhibiting efficacy in PDAC model. • The self-developed antibody structure NY004 is a promising drug platform for radioimmunotheranostics of CEACAM6-positive tumors including pancreatic ductal adenocarcinoma.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kong, Xie, Zhang, et al. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma. Eur Radiol. 2023. PMID: 37166496. doi:10.1007/s00330-023-09679-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。